deltatrials
Terminated PHASE3 INTERVENTIONAL 3-arm NCT04504734

Bucillamine in Treatment of Patients With COVID-19

Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients With Mild-Moderate COVID-19

Sponsor: Revive Therapeutics, Ltd.

Conditions Covid19
Updated 20 times since 2020 Last updated: Jul 5, 2023 Started: Nov 27, 2020 Primary completion: Jun 12, 2023 Completion: Jun 12, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Met definition of futility according to DSMB

This PHASE3 trial investigates Covid19 and is currently terminated or withdrawn. Revive Therapeutics, Ltd. leads this study, which shows 20 recorded versions since 2020 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~May 2022 · 2 months · monthly snapshot~May 2022 – ~Nov 2022 · 6 months · monthly snapshot~Nov 2022 – ~Jul 2023 · 8 months · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

20 versions recorded
  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  4. Aug 2023 — Jul 2024 [monthly]

    Terminated PHASE3

  5. Jul 2023 — Aug 2023 [monthly]

    Terminated PHASE3

    Status: Enrolling By InvitationTerminated

Show 15 earlier versions
  1. Nov 2022 — Jul 2023 [monthly]

    Enrolling By Invitation PHASE3

  2. May 2022 — Nov 2022 [monthly]

    Enrolling By Invitation PHASE3

  3. Mar 2022 — May 2022 [monthly]

    Enrolling By Invitation PHASE3

  4. Feb 2022 — Mar 2022 [monthly]

    Enrolling By Invitation PHASE3

  5. Dec 2021 — Feb 2022 [monthly]

    Enrolling By Invitation PHASE3

  6. Oct 2021 — Dec 2021 [monthly]

    Enrolling By Invitation PHASE3

  7. Sep 2021 — Oct 2021 [monthly]

    Enrolling By Invitation PHASE3

  8. Jun 2021 — Sep 2021 [monthly]

    Enrolling By Invitation PHASE3

  9. May 2021 — Jun 2021 [monthly]

    Enrolling By Invitation PHASE3

  10. Mar 2021 — May 2021 [monthly]

    Enrolling By Invitation PHASE3

  11. Feb 2021 — Mar 2021 [monthly]

    Enrolling By Invitation PHASE3

  12. Jan 2021 — Feb 2021 [monthly]

    Enrolling By Invitation PHASE3

  13. Dec 2020 — Jan 2021 [monthly]

    Enrolling By Invitation PHASE3

  14. Oct 2020 — Dec 2020 [monthly]

    Enrolling By Invitation PHASE3

    Status: Not Yet RecruitingEnrolling By Invitation

  15. Sep 2020 — Oct 2020 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Revive Therapeutics, Ltd.
Data source: Revive Therapeutics, Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .